ProBioGen enters into an evaluation programme with major vaccines company for the testing of cell lines

05-Oct-2004

Berlin. ProBioGen AG announced that it has entered into a joint programme with Chiron vaccines, a business unit of Chiron Corporation, to evaluate ProBioGen´s vaccine cell lines for vaccine production.

Under the programme, ProBioGen will cultivate several of its new cell lines which have been derived from various primary tissues under pre-selected conditions. Chiron Vaccines will perform testing on these cell lines for comparison against currently employed vaccine cell substrates for virus propagation and productivity. Both parties reserve option rights to enter into collaboration for the further development of cell lines for specific vaccine applications.

"This Programme will underline and prove the superiority of our cell line development expertise. ProBioGen has significant know how in providing vaccine manufacturers the necessary starting material to enhance efficiency which ultimately translates into higher productivity and lower costs," said Michael Schlenk CEO of ProBioGen.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies

How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies

Novel gene variants identified in male breast cancer

Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

TranScrip Partners appoints David Oxlade as Chairman of the Board

Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents

Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections - Second part of the study in the target population of elderly subjects will be initiated

Excellent early results in large OvPlex ovarian cancer biomarker study

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board